349 related articles for article (PubMed ID: 27521328)
21. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Padron E; Dezern A; Andrade-Campos M; Vaddi K; Scherle P; Zhang Q; Ma Y; Balasis ME; Tinsley S; Ramadan H; Zimmerman C; Steensma DP; Roboz GJ; Lancet JE; List AF; Sekeres MA; Komrokji RS;
Clin Cancer Res; 2016 Aug; 22(15):3746-54. PubMed ID: 26858309
[TBL] [Abstract][Full Text] [Related]
22. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
24. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
[TBL] [Abstract][Full Text] [Related]
26. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
27. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
28. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
29. Topotecan in the treatment of hematologic malignancies.
Beran M; Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
31. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
32. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Waisbren J; Dinner S; Altman J; Frankfurt O; Helenowski I; Gao J; McMahon BJ; Stein BL
Int J Hematol; 2017 Jan; 105(1):44-51. PubMed ID: 27558575
[TBL] [Abstract][Full Text] [Related]
33. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
34. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
36. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
37. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
39. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
40. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
